Eupraxia Pharmaceuticals expands trial of eosinophilic esophagitis therapy [Yahoo! Finance]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Yahoo! Finance
The expansion follows promising initial data and aims to explore higher doses and longer follow-up periods in additional trial subjects. The dose-escalation, multi-centre, open-label study is designed to assess the safety, pharmacokinetics, tolerability, and efficacy of EP-104GI in adult patients with active EoE. EP-104GI is administered through injections directly into the oesophageal wall. Initial low-dose cohorts have shown potential efficacy and safety, leading to the decision to expand the trial. This could pave the way for a registration trial set to commence next year. The protocol amendment cleared by the Australian Health Authority and Health Canada includes new doses and an increase in the number of injection sites. The participant count is set to rise from 12-15 to 27-33, with an additional 10-24 participants to be enrolled in dose confirmation cohorts. To assess the longer-term effects of EP-104GI, the follow-up duration has been extended to 52 weeks for tho
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of ShareholdersPR Newswire
- Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024PR Newswire
- Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic EsophagitisPR Newswire
EPRX
Sec Filings
- 6/6/24 - Form 6-K
- 6/5/24 - Form 6-K
- 5/23/24 - Form 6-K
- EPRX's page on the SEC website